<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03331198</url>
  </required_header>
  <id_info>
    <org_study_id>017004</org_study_id>
    <secondary_id>TRANSCEND-CLL-004</secondary_id>
    <nct_id>NCT03331198</nct_id>
  </id_info>
  <brief_title>Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)</brief_title>
  <official_title>An Open-Label, Phase 1/2 Study of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Juno Therapeutics, a Subsidiary of Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Juno Therapeutics, a Subsidiary of Celgene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of
      JCAR017 in adult subjects with relapsed or refractory CLL or SLL. The study will include a
      Phase 1 part to determine the recommended dose of JCAR017 monotherapy in subjects with
      relapsed or refractory CLL or SLL, followed by a Phase 2 part to further assess the efficacy
      and safety of JCAR017 monotherapy treatment at the recommended dose. A separate Phase 1
      cohort will assess the combination of JCAR017 and concurrent ibrutinib. In all subjects, the
      safety, efficacy, and pharmacokinetics (PK) of JCAR017 will be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 26, 2017</start_date>
  <completion_date type="Anticipated">July 14, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 12, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase 1: subjects will be assigned to receive JCAR017, or JCAR017 + ibrutinib Phase 2: subjects will be assigned to receive JCAR017 at the recommended dose</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1 monotherapy arm: recommended dose</measure>
    <time_frame>28 days</time_frame>
    <description>Recommended dose based on assessment of data from each dose level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1 combination therapy arm: adverse events</measure>
    <time_frame>Through post-treatment Month 24</time_frame>
    <description>Proportion of subjects experiencing adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1 combination therapy arm: laboratory abnormalities</measure>
    <time_frame>Through post-treatment Month 24</time_frame>
    <description>Proportion of subjects experiencing laboratory abnormalities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: rate of complete remission (CR)</measure>
    <time_frame>Through post-treatment Month 24</time_frame>
    <description>Proportion of subjects who have CR after JCAR017 infusion based on Independent Review Committee (IRC) assessment using International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2018 guidelines</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 2: overall response rate</measure>
    <time_frame>Through post-treatment Month 24</time_frame>
    <description>Overall response rate based on IRC assessment using iwCLL 2018 guidelines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: minimal residual disease (MRD)-negative response rate</measure>
    <time_frame>Through post-treatment Month 24</time_frame>
    <description>MRD will be measured via IgHV deep sequencing and flow cytometry of peripheral blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: adverse events</measure>
    <time_frame>Through post-treatment Month 24</time_frame>
    <description>Proportion of subjects experiencing adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: laboratory abnormalities</measure>
    <time_frame>Through post-treatment Month 24</time_frame>
    <description>Proportion of subjects experiencing laboratory abnormalities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: overall survival</measure>
    <time_frame>Through post-treatment Month 24</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: progression-free survival (PFS)</measure>
    <time_frame>Through post-treatment Month 24</time_frame>
    <description>PFS, defined as the time from JCAR017 infusion to disease progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: health economics and outcomes research</measure>
    <time_frame>Through post-treatment Month 24</time_frame>
    <description>EuroQol instrument EQ-5D-5L and numbers of intensive care unit (ICU) inpatient days and non-ICU inpatient days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: health-related quality of life</measure>
    <time_frame>Through post-treatment Month 24</time_frame>
    <description>EORTC QLQ-C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: health-related quality of life</measure>
    <time_frame>Through post-treatment Month 24</time_frame>
    <description>CLL-specific module QLQ-CLL-17</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Leukemia, Lymphocytic, Chronic, B-Cell</condition>
  <condition>Lymphoma, Small Lymphocytic</condition>
  <arm_group>
    <arm_group_label>Phase 1 JCAR017 monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be assigned to receive JCAR017 (lisocabtagene maraleucel)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1 JCAR017 + ibrutinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receiving ibrutinib at baseline will be assigned to receive JCAR017 (lisocabtagene maraleucel) at the recommended dose + ibrutinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 JCAR017 monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive JCAR017 (lisocabtagene maraleucel) at the recommended dose from the Phase 1 monotherapy arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>JCAR017 (lisocabtagene maraleucel)</intervention_name>
    <description>Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive bridging chemotherapy for disease control. Upon successful generation of JCAR017 product, participants will receive treatment with JCAR017 therapy. Each cycle will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection.</description>
    <arm_group_label>Phase 1 JCAR017 monotherapy</arm_group_label>
    <arm_group_label>Phase 2 JCAR017 monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>JCAR017 (lisocabtagene maraleucel) + ibrutinib</intervention_name>
    <description>Participants eligible for this cohort should be receiving ibrutinib at the time of screening. For participants who previously discontinued ibrutinib, ibrutinib will be started as soon as possible after eligibility is confirmed. Ibrutinib treatment will continue for up to 90 days after JCAR017 infusion (or longer for participants who are receiving benefit from ibrutinib). Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive bridging chemotherapy for disease control. Upon successful generation of JCAR017 product, participants will receive treatment with JCAR017 therapy. Each cycle will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection.</description>
    <arm_group_label>Phase 1 JCAR017 + ibrutinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of:

               1. CLL with an indication for treatment based on the Investigator's opinion and
                  measurable disease, or

               2. SLL (lymphadenopathy and/or splenomegaly and &lt; 5×10^9 CD19+ CD5+ clonal B
                  lymphocytes/L [&lt; 5000/µL] in the peripheral blood at diagnosis with measurable
                  disease that is biopsy-proven SLL)

          -  Subjects (other than those in the ibrutinib + JCAR017 combination therapy cohort) must
             have received and failed Bruton tyrosine kinase inhibitor (BTKi) treatment or have
             been deemed ineligible for BTKi therapy.

          -  Subjects (other than those in the ibrutinib + JCAR017 combination therapy cohort) must
             have received previous treatment as follows:

               1. Subjects with CLL or SLL and high-risk features must have failed at least 2 lines
                  of prior therapy.

               2. Subjects with CLL or SLL and standard-risk features must have failed at least 3
                  lines of prior therapy.

          -  Subjects in the ibrutinib + JCAR017 combination therapy cohort must either:

               1. be receiving ibrutinib and progressing at the time of study enrollment

               2. be receiving ibrutinib for at least 6 months with a response less than complete
                  response/remission (CR) and have high-risk features as defined in inclusion
                  criterion 5a

               3. have BTK or PLCgamma2 mutations per local laboratory assessment, with or without
                  progression on ibrutinib

               4. have previously received ibrutinib and have no contraindications to restarting
                  ibrutinib

          -  Eastern Cooperative Oncology Group performance status of ≤ 1

          -  Assessed by the Investigator to have adequate bone marrow function to receive
             lymphodepleting chemotherapy

          -  Adequate organ function, defined as:

               1. Serum creatinine ≤ 1.5 × age-adjusted upper limit of normal (ULN) OR calculated
                  creatinine clearance &gt; 30 mL/min

               2. Alanine aminotransferase ≤ 5 × ULN and total bilirubin &lt; 2.0 mg/dL (or &lt; 3.0
                  mg/dL for subjects with Gilbert's syndrome or leukemic infiltration of the liver)

               3. Adequate pulmonary function, defined as ≤ Common Terminology Criteria for Adverse
                  Events (CTCAE) Grade 1 dyspnea and saturated oxygen (SaO2) ≥ 92% on room air

               4. Adequate cardiac function, defined as left ventricular ejection fraction ≥ 40% as
                  assessed by echocardiogram or multiple uptake gated acquisition scan performed
                  within 30 days prior to determination of eligibility

          -  Subject either currently has central vascular access or is a candidate to receive
             central vascular access or peripheral vascular access for leukapheresis procedure.

          -  If prior CD19-targeted therapy has been administered, subject must have CD19-positive
             disease confirmed by immunohistochemistry or flow cytometry since completing the prior
             CD19-targeted therapy.

        Exclusion Criteria:

          -  Subjects with known active central nervous system (CNS) involvement by malignancy.
             Those with prior CNS disease that has been effectively treated will be eligible if
             treatment was completed at least 3 months prior to enrollment with no evidence of
             symptomatic disease and stable abnormalities on repeat imaging.

          -  History of another primary malignancy that has not been in remission for at least 2
             years. (The following are exempt from the 2-year limit: nonmelanoma skin cancer,
             completely resected stage 1 solid tumor with low risk for recurrence, curatively
             treated localized prostate cancer, cervical carcinoma in situ on biopsy or a squamous
             intraepithelial lesion on Pap smear, and in situ breast cancer that has been
             completely resected.)

          -  Subjects with Richter's transformation

          -  Prior treatment with any gene therapy product

          -  Active hepatitis B, active hepatitis C, or active human immunodeficiency virus (HIV)
             infection

          -  Systemic fungal, bacterial, viral, or other infection that is not controlled

          -  Presence of acute or extensive chronic graft versus host disease (GVHD)

          -  History of any one of the following cardiovascular conditions within the past 6
             months: Class III or IV heart failure as defined by the New York Heart Association
             (NYHA), cardiac angioplasty or stenting, myocardial infarction, unstable angina, or
             other clinically significant cardiac disease

          -  History or presence of clinically relevant CNS pathology such as epilepsy, generalized
             seizure disorder, aphasia, stroke with current neurologic sequelae, severe brain
             injuries, dementia, Parkinson's disease, cerebellar disease,cerebral edema, or
             psychosis

          -  Pregnant or nursing (lactating) women

          -  Use of any of the following medications or treatments within the noted time prior to
             leukapheresis:

               1. Alemtuzumab within 6 months prior to leukapheresis

               2. Allogeneic hematopoietic stem cell transplant within 100 days prior to
                  leukapheresis

               3. Cladribine within 3 months prior to leukapheresis

               4. Donor lymphocyte infusions (DLI) within 2 months prior to leukapheresis

               5. Radiation including large bone marrow fields such as sternum or pelvis within 6
                  weeks prior to leukapheresis

               6. Fludarabine within 4 weeks prior to leukapheresis

               7. GVHD therapies such as calcineurin inhibitors, methotrexate or other
                  chemotherapeutics, mycophenolate mofetil, rapamycin, or immunosuppressive
                  antibodies (such as anti-tumor necrosis factor-α [TNFα], anti-interleukin-6
                  [IL-6], or anti-interleukin-6 receptor [IL 6R]) within 4 weeks prior to
                  leukapheresis

               8. Cyclophosphamide, ifosfamide, bendamustine, chlorambucil, or melphalan within 2
                  weeks prior to leukapheresis

               9. Therapeutic doses of corticosteroids (defined as &gt; 20 mg/day prednisone or
                  equivalent) within 7 days prior to leukapheresis

              10. Anti-CD20 monoclonal antibodies within 7 days prior to leukapheresis

              11. Venetoclax within 4 days prior to leukapheresis

              12. Idelalisib or duvelisib within 2 days prior to leukapheresis

              13. Lenalidomide within 1 day prior to leukapheresis

              14. Experimental agents, including off-label use of approved drugs (with the
                  exception of acalabrutinib which may be continued up to the day before
                  leukapheresis), within 4 weeks prior to leukapheresis unless progression is
                  documented on the experimental therapy and at least 3 half-lives have elapsed
                  prior to leukapheresis

          -  Uncontrolled medical, psychological, familial, sociological, or geographical
             conditions that do not permit compliance with the protocol, as judged by the
             Investigator; or subject unwillingness or inability to follow the procedures required
             in the protocol

          -  Progressive vascular tumor invasion, thrombosis, or embolism

          -  Deep vein thrombosis or embolism not managed on a stable regimen of anticoagulation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heidi Gillenwater, MD</last_name>
    <role>Study Director</role>
    <affiliation>Juno Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Associate Director Clinical Trial Disclosure</last_name>
    <phone>1-888-260-1599</phone>
    <email>clinicaltrialdisclosure@celgene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Hill</last_name>
      <phone>205-996-8023</phone>
      <email>tiffanydhill@uabmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Danielle Mussey</last_name>
      <phone>205-996-1795</phone>
      <email>dmussey@uabmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Amitkumar Mehta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenda Noggy</last_name>
      <phone>480-256-3425</phone>
      <email>brenda.noggy@bannerhealth.com</email>
    </contact>
    <investigator>
      <last_name>Rajneesh Nath, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hormoz Mirshkarlo, MD</last_name>
      <phone>626-256-4673</phone>
      <phone_ext>69074</phone_ext>
      <email>hmirshkarlo@coh.org</email>
    </contact>
    <investigator>
      <last_name>Tanya Siddiqi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krisma C Montalvo</last_name>
      <phone>858-246-0386</phone>
      <email>kcmontalvo@ucsd.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kimberly Aguilar</last_name>
      <phone>858-534-5201</phone>
      <email>k1aguilar@ucsd.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Thomas J Kipps, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joy Valadez</last_name>
      <phone>310-794-6500</phone>
      <email>jvaladez@mednet.ucla.edu</email>
    </contact>
    <contact_backup>
      <last_name>Anna Crosetti</last_name>
      <phone>310-794-6500</phone>
      <email>acrosetti@mednet.ucla.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Herbert Eradat, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Chon</last_name>
      <phone>415-476-2351</phone>
      <email>andrew.chon@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Lawrence Kaplan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenny Crawford</last_name>
      <phone>202-687-0038</phone>
      <email>crawfojg@georgetown.edu</email>
    </contact>
    <investigator>
      <last_name>Pashna Munshi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed Kharfan-Dabaja, MD</last_name>
      <phone>904-953-2000</phone>
      <email>kharfandabaja.mohamed@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Teresa Banda</last_name>
      <phone>214-820-1660</phone>
      <email>teresa.banda@bswhealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Mohamed Kharfan-Dabaja, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Blood and Marrow Transplant Group of Georgia (BMTGA)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott R Solomon, MD</last_name>
      <phone>404-255-1930</phone>
      <email>ssolomon@bmtga.com</email>
    </contact>
    <contact_backup>
      <last_name>Stacey Brown</last_name>
      <phone>404-780-7965</phone>
      <email>Stacey.brown@northside.com</email>
    </contact_backup>
    <investigator>
      <last_name>Scott R Solomon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>312-695-1301</phone>
      <email>cancertrials@northwestern.edu</email>
    </contact>
    <contact_backup>
      <last_name>Arezou Ireta</last_name>
      <phone>312-695-8169</phone>
      <email>a-ireta@northwestern.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Shuo Ma, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sadi Dixon, RN</last_name>
      <phone>773-702-2070</phone>
      <email>sdixon2@medicine.bsd.uchicago.edu</email>
    </contact>
    <contact_backup>
      <last_name>Elaine Hoekstra</last_name>
      <phone>773-884-8528</phone>
      <email>ehoekstra1@medicine.bsd.uchicago.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Peter Riedell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacob D Soumerai, MD</last_name>
      <phone>617-724-4000</phone>
      <email>jsoumerai@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Jacob D Soumerai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emma Logan, RN</last_name>
      <phone>617-667-5984</phone>
      <email>eklogan@bidmc.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Pavania Elavalakanar</last_name>
      <phone>617-667-1903</phone>
      <email>pelavala@bidmc.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jon Arnason, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-5362</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>U of M Cancer Answerline</last_name>
      <phone>800-865-1125</phone>
    </contact>
    <investigator>
      <last_name>Monalisa Ghosh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joo En Kim, MPH</last_name>
      <phone>313-576-8030</phone>
      <email>kimjo@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Abhinav Deol, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Referral Office</last_name>
      <phone>855-776-0015</phone>
    </contact>
    <contact_backup>
      <last_name>Gabrielle Bouska</last_name>
      <phone>507-538-0586</phone>
      <email>bouska.gabrielle@mayo.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Saad Kenderian, MB, ChB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gail A Paulsen</last_name>
      <phone>402-559-3853</phone>
      <email>gpaulsen@unmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lindsay Hicks</last_name>
      <phone>402-559-6044</phone>
      <email>lindsay.hick@unmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Julie Vose, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kara Yannotti, RNC</last_name>
      <phone>551-996-5168</phone>
      <email>Kara.Yannotti@Hackensackmeridian.org</email>
    </contact>
    <investigator>
      <last_name>Tatyana Feldman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oona Harrigan</last_name>
      <phone>732-235-5609</phone>
      <email>oh77@cinj.rutgers.edu</email>
    </contact>
    <contact_backup>
      <last_name>Roger Strair, MD, PhD</last_name>
      <phone>732-235-4523</phone>
      <email>strairrk@cinj.rutgers.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Roger Strair, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanna Weissbrot</last_name>
      <phone>212-304-5558</phone>
      <email>hw2432@cumc.columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sarah Leach</last_name>
      <phone>212-304-5585</phone>
      <email>sl3971@cumc.columbia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Nicole Lamanna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>June Greenburg</last_name>
      <phone>212-746-2651</phone>
      <email>jdg2002@med.cornell.edu</email>
    </contact>
    <contact_backup>
      <last_name>Koen Van Besien</last_name>
      <phone>212-746-2048</phone>
      <email>kov9001@med.cornell.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Koen Van Besien, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Stowe</last_name>
      <phone>919-681-4769</phone>
      <email>rachel.stowe@duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Danielle M Brander, MD</last_name>
      <phone>919-684-8964</phone>
      <email>danielle.brander@duke.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Danielle M Brander, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Seidman Cancer Center (Case Western)</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5061</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Caimi, MD</last_name>
      <phone>216-844-3951</phone>
      <email>Paolo.Caimi@UHhospitals.org</email>
    </contact>
    <contact_backup>
      <last_name>Yeritza Hernandez-Collazo, MS</last_name>
      <phone>216-844-3951</phone>
      <email>Yeritza.Hernandez-Collazo@UHhospitals.org</email>
    </contact_backup>
    <investigator>
      <last_name>Paolo Caimi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center (Stephenson Cancer Center)</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Asch, MD</last_name>
      <phone>405-271-8000</phone>
      <email>adam-asch@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Adam Asch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Perelman Center for Advanced Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Schuster, MD</last_name>
      <phone>215-662-6065</phone>
      <email>stephen.schuster@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Stephen Schuster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison Scott</last_name>
      <phone>215-955-5903</phone>
      <email>allison.scott@jefferson.edu</email>
    </contact>
    <investigator>
      <last_name>Matthew Carabasi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Fukas</last_name>
    </contact>
    <contact_backup>
      <phone>412-623-6037</phone>
      <email>fukaslj@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kathleen Dorritie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Houston E Holmes III, MD, FACP</last_name>
      <phone>214-370-1077</phone>
    </contact>
    <investigator>
      <last_name>Houston E Holmes III, MD, FACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Courtney Saltarski</last_name>
      <phone>214-648-7030</phone>
      <email>courtney.saltarski@utsouthwestern.edu</email>
    </contact>
    <contact_backup>
      <last_name>Farrukh Awan, MD</last_name>
      <phone>214-648-4077</phone>
      <email>farrukh.awan@utsouthwestern.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Farrukh Awan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William G Wierda, MD, PhD</last_name>
      <phone>713-792-7026</phone>
      <email>wwierda@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>William G Wierda, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kolleen Hicks, BS</last_name>
      <phone>801-587-7604</phone>
      <email>Kolleen.Hicks@hci.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Deborah Stephens, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John McCarty, MD</last_name>
      <phone>804-628-2760</phone>
      <email>jmccarty@vcu.edu</email>
    </contact>
    <investigator>
      <last_name>John McCarty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SCCA Immunotherapy Trials Intake</last_name>
      <phone>206-606-4668</phone>
      <email>immunotherapy@seattlecca.org</email>
    </contact>
    <investigator>
      <last_name>David Maloney, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nirav Shah, MD</last_name>
      <phone>414-805-4600</phone>
      <email>nishah@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Nirav Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 29, 2017</study_first_submitted>
  <study_first_submitted_qc>November 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>June 1, 2020</last_update_submitted>
  <last_update_submitted_qc>June 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>JCAR017</keyword>
  <keyword>chimeric antigen receptor</keyword>
  <keyword>CLL</keyword>
  <keyword>SLL</keyword>
  <keyword>chronic lymphocytic leukemia</keyword>
  <keyword>small lymphocytic lymphoma</keyword>
  <keyword>CAR</keyword>
  <keyword>CAR T cells</keyword>
  <keyword>autologous T cell therapy</keyword>
  <keyword>immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

